EMA Application withdrawn: Spanidin (gusperimus trihydrochloride) — Euro Nippon Kayaku GmbH

View source ↗

Summary

EU application for Spanidin (gusperimus trihydrochloride) withdrawn; previously targeted Wegener Granulomatosis (granulomatosis with polyangiitis).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Granulomatosis with Polyangiitis
• Wegener Granulomatosis

Drugs mentioned

• Spanidin (gusperimus)

Snippet

Status: Application withdrawn. Therapeutic area: Wegener Granulomatosis. MAH: Euro Nippon Kayaku GmbH. Decision date: 31/12/2009. Orphan medicine